COX-2 specific inhibitors in NSAID-intolerant patients

Area of Science:

• Immunology
• Pharmacology
• Respiratory Medicine

Background:

• Adverse reactions to NSAIDs, including respiratory and skin issues, are often mediated by cyclooxygenase-1 (COX-1) inhibition, leading to increased cysteinyl leukotrienes (Cys-LTs).
• NSAID-induced asthma is associated with reduced prostaglandin E2 (PGE2) production, potentially due to insufficient cyclooxygenase-2 (COX-2) expression.
• PGE2 inhalation can inhibit NSAID-induced bronchoconstriction and Cys-LTs release, suggesting reduced PGE2 synthesis increases susceptibility to NSAID effects.

Purpose of the Study:

• To investigate the role of COX enzymes in NSAID intolerance.
• To evaluate the safety and efficacy of selective COX-2 inhibitors in NSAID-sensitive patients.

Main Methods:

• Review of recent studies on NSAID-induced respiratory and skin reactions.
• Analysis of the effects of COX-1 and COX-2 inhibition on Cys-LTs and PGE2 production.
• Assessment of patient tolerance to selective COX-2 inhibitors (rofecoxib, celecoxib).

Main Results:

• Selective COX-2 inhibitors are generally well-tolerated by NSAID-sensitive patients and do not increase Cys-LTs production.
• However, COX-2 inhibitors can still trigger cutaneous reactions in some patients with a history of NSAID-induced skin issues.
• NSAID intolerance exhibits heterogeneity, indicating individual variability in response to NSAIDs and related drugs.

Conclusions:

• The mechanism of NSAID intolerance involves complex interactions between COX-1, COX-2, and leukotriene pathways.
• While selective COX-2 inhibitors offer an alternative for NSAID-sensitive individuals, caution is advised due to potential skin reactions.
• Supervised administration by specialists is recommended for NSAID-intolerant patients considering coxibs due to the syndrome's heterogeneous nature.